HW
CPRX

Hancock Whitney’s Catalyst Pharmaceutical CPRX Stock Holding History

Hancock Whitney’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$818K Buy
26,031
+102
+0.4% +$3.01K 0.01% 476
2026
Q1 		$729K Sell
25,929
-7,019
-21% -$167K 0.01% 484
2025
Q4 		$769K Buy
32,948
+292
+0.9% +$6.5K 0.01% 465
2025
Q3 		$643K Sell
32,656
-5,629
-15% -$116K 0.01% 516
2025
Q2 		$831K Sell
38,285
-562
-1% -$13.3K 0.02% 459
2025
Q1 		$942K Buy
38,847
+525
+1% +$11.8K 0.03% 324
2024
Q4 		$800K Sell
38,322
-606
-2% -$13K 0.03% 344
2024
Q3 		$774K Sell
38,928
-1,928
-5% -$35.7K 0.02% 362
2024
Q2 		$633K Buy
40,856
+88
+0.2% +$1.37K 0.02% 373
2024
Q1 		$650K Buy
40,768
+12,361
+44% +$186K 0.02% 376
2023
Q4 		$478K Sell
28,407
-470
-2% -$6.42K 0.02% 450
2023
Q3 		$338K Sell
28,877
-65
-0.2% -$869 0.01% 501
2023
Q2 		$388K Buy
28,942
+14,227
+97% +$205K 0.02% 478
2023
Q1 		$244K Sell
14,715
-103
-0.7% -$1.7K 0.01% 578
2022
Q4 		$275K Buy
+14,818
New +$228K 0.01% 550
2021
Q3 		– Sell
-238,281
Closed -$1.37M – 696
2021
Q2 		$1.37M Sell
238,281
-208
-0.1% -$1.07K 0.04% 353
2021
Q1 		$1.1M Sell
238,489
-803
-0.3% -$3.19K 0.04% 390
2020
Q4 		$799K Sell
239,292
-53,928
-18% -$181K 0.03% 426
2020
Q3 		$871K Sell
293,220
-24,690
-8% -$96.5K 0.03% 396
2020
Q2 		$1.47M Buy
+317,910
New +$1.43M 0.06% 295

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Hancock Whitney's CPRX Position: Q2 2026 in Review

Hancock Whitney increased its Catalyst Pharmaceutical (CPRX) stake by 0.39% in Q2 2026, buying an estimated $3.01K and bringing the position to 26,031 shares worth $818K. The position accounts for 0.01% of the portfolio, ranked #476.

Hancock Whitney first reported a position in CPRX in Q2 2020 and has held it in 20 quarters since. The position peaked at $1.47M in Q2 2020. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Hancock Whitney held 26,031 shares of Catalyst Pharmaceutical worth $818K as of Q2 2026.
  • Hancock Whitney bought 102 Catalyst Pharmaceutical shares in Q2 2026, an estimated $3.01K.
  • Catalyst Pharmaceutical made up 0.01% of Hancock Whitney's portfolio in Q2 2026, its #476 holding.
  • Hancock Whitney first reported a position in Catalyst Pharmaceutical in Q2 2020 and has held it in 20 quarters since.
  • Hancock Whitney's Catalyst Pharmaceutical position peaked at $1.47M in Q2 2020.
  • 395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Hancock Whitney's 13F filing for Q2 2026, filed 14 Aug 2026.